Ligand Pharmaceuticals LGND Teriparatide injection — Total revenue and income

Similar metrics at other companies

TVTXTiopronin products — Total Revenue

$19.34M-3.2%

AMGNRepatha — Total revenues

$876M+33.5%

AMGNRepatha — Total revenues

$754M+35.7%

VCYTBiopharmaceutical revenue — Total Revenue

$301K-86.9%

INCYProduct royalty revenues — Total revenues

$151.19M+15.7%

AMGNTEPEZZA — Total revenues

$490M+28.6%

Questions, answered.

What is Ligand Pharmaceuticals's teriparatide injection — total revenue and income?

Ligand Pharmaceuticals (LGND) reported teriparatide injection — total revenue and income of $1.32M in Q1 2026.

How has Ligand Pharmaceuticals's teriparatide injection — total revenue and income changed year-over-year?

Ligand Pharmaceuticals's teriparatide injection — total revenue and income increased by 10.9% year-over-year, from $1.19M to $1.32M.

What is the long-term trend for Ligand Pharmaceuticals's teriparatide injection — total revenue and income?

Over 4 years (2021 to 2025), Ligand Pharmaceuticals's teriparatide injection — total revenue and income has grown at a 11.6% compound annual growth rate (CAGR), from $5.26M to $8.15M.

What does teriparatide injection — total revenue and income mean?

This metric captures the total economic value derived from the Teriparatide injection asset, specifically focusing on royalty streams and associated licensing income. It reflects the underlying commercial success of the drug as marketed by partners and the effectiveness of the company's intellectual property monetization strategy. Tracking this revenue stream provides insight into the sustainability and long-term cash flow potential of the company's drug development partnerships.